Inobrodib [ino-bro-dib
]
A first in class oral anti-cancer drug
Inobrodib is a small molecule inhibitor, taken orally as a capsule. It inhibits p300 and CBP through binding into the conserved bromodomain of the twin proteins. This impacts the expression of key cancer drivers, including MYC and IRF4. Different cancer indications can be targeted by inobrodib as monotherapy or in combination with existing standard of care drugs. It is the most advanced drug of its type.
The science behind inobrodib
Inobrodib is a small molecule inhibitor drug, developed by CellCentric from initial chemical hits, through to an optimized compound and onto a clinical candidate.
Inhibiting p300/CBP impacts the expression of key cancer drivers
Inobrodib displaces p300/CBP, and as a result, impacts the expression of key cancer driving genes. MYC and IRF4 in particular are significantly affected by p300/CBP inhibition. They are important in progression of hematological malignancies. p300/CBP inhibition also impacts the androgen receptor expression, which is critical in late-stage prostate cancer.
An oral treatment for real world settings
Inobrodib is a new type of investigational treatment for people with cancer. Delivered as an oral capsule, it is easy for patients to take. Inobrodib can be taken at home without the need for intensive monitoring. As it has a good safety profile for a drug in this setting, it can also be used by those who are unable to tolerate other treatments, including the elderly and frail.
Targeting the bromodomain of p300 and CBP
A differentiated and highly selective inhibitor
There are over 60 different bromodomains on cellular proteins, many of which constitute potential drug targets.
Inobrodib is highly selective for the specific conserved bromodomain of p300 and CBP and shows excellent selectivity against other bromodomains such as BRD1, BRD2, BRD3 and BRD4. Unlike inhibitors that target the HAT catalytic site, or degraders (e.g. PROTACs) that eliminate p300/CBP, inobrodib selectively displaces p300/CBP from regions of the chromatin that are important for oncogenic activity.
Inobrodib’s action can be synergistic with BET inhibitors, whilst impacting the expression of 7x fewer genes (compared to JQ1).
In breadth-of-efficacy cell panel testing, inobrodib has a very specific effect on clusters of cancer types, rather than being generally cytotoxic.
Enhancing standard of care agent efficacy
Inobrodib combines well with a number of approved therapies. Inobrodib can synergize with IMiDs, potentiate immune checkpoint inhibitors, and enhance the activity of DNA damage repair inhibitors.
Scientific publications, posters and presentations
View and download posters from recent key conferences
Tolerability and clinical activity of novel first-in-class oral agent, inobrodib (CCS1477), in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies
CellCentric’s Director of Cancer Biology talks inobrodib’s mechanism of action in the context of latest efficacy and safety data, treating late/last stage multiple myeloma
Tolerability and clinical activity of novel first in class oral agent, inobrodib (CCS1477), in combination with pomalidomide and dexamethasone in relapsed/ refractory multiple myeloma